Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
NCT05211154 · Danish Headache Center · PHASE4 · terminated · last registry update 2025-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Issues with recruitment” | – | Registry record, Danish Headache Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGS2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-09Also stopped (terminated): Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2025-07-18Results posted on the registry: Columbia University, I 124-Evuzamitide (NCT05635045)
- 2025-03-11Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) (NCT06871046)
- 2025-03-10Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) + Placebo Patch (NCT06866613)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision